Search

Immunocore Holdings PLC ADR

Открыт

33.07 -0.09

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

32.1

Макс.

33.58

Ключевые показатели

By Trading Economics

Доход

43M

13M

Продажи

29M

107M

Прибыль на акцию

0.25

Рентабельность продаж

12.139

Сотрудники

524

EBITDA

25M

17M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+111.53% upside

Дивиденды

By Acuity

Следующий отчет о доходах

6 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

200M

1.6B

Предыдущая цена открытия

33.16

Предыдущая цена закрытия

33.07

Immunocore Holdings PLC ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 19:51 UTC

Immunocore Holdings PLC shares are higher today amid broader market strength and a notable decline in crude oil prices, easing inflation concerns.

3 авг. 2026 г., 20:03 UTC

News

Immunocore Holdings PLC is declining in Monday's session, diverging from gains in major tech stocks and remaining below its 20-day moving average.

31 июл. 2026 г., 20:06 UTC

Immunocore Holdings PLC shares are lower today, with no specific news identified. The stock has fluctuated within a routine range during the session.

28 июл. 2026 г., 19:56 UTC

Immunocore Holdings PLC shares are lower today, continuing a three-session decline amid broader market sentiment influenced by declines in Asian markets.

27 июл. 2026 г., 18:06 UTC

Immunocore Holdings PLC shares are lower today, reflecting a broader market trend amid a significant decline in oil prices. No specific company news was identified.

24 июл. 2026 г., 15:26 UTC

Immunocore Holdings PLC shares are lower today, having declined from a session high. This movement occurs amid mixed labor market data and inflation concerns.

22 июл. 2026 г., 19:16 UTC

News

Immunocore Holdings PLC shares are higher as Wall Street Zen upgraded its rating to "buy," despite a mixed analyst outlook.

21 июл. 2026 г., 21:01 UTC

Immunocore Holdings PLC shares are higher in after-market trading, driven by optimistic sentiment in U.S. markets and better-than-expected results from major companies.

20 июл. 2026 г., 20:06 UTC

News

Immunocore Holdings PLC shares are lower amid broader market weakness. Analyst ratings show mixed sentiment, with upgrades and downgrades influencing performance.

Сравнение c конкурентами

Изменение цены

Immunocore Holdings PLC ADR Прогноз

Целевая цена

By TipRanks

111.53% рост

Прогноз на 12 месяцев

Средняя 68.6 USD  111.53%

Максимум 100 USD

Минимум 35 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Immunocore Holdings PLC ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

4

Покупка

1

Удержание

1

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
help-icon Live chat